Cyclophosphamide activates ferroptosis-induced dysfunction of Leydig cells via SMAD2 pathway
Biology of Reproduction · 2024
DOI: 10.1093/biolre/ioae020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of Reproduction, 2024. Verfasst von Senlin Liao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, PR China. Hauptthemen laut MEDLINE: Cyclophosphamide, Ferroptosis, Leydig Cells, Smad2 Protein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Third Affiliated Hospital of Southern Medical University President's Fund, Third Affiliated Hospital of Southern Medical University President’s Fund.
Abstract (Originalsprache)
Cyclophosphamide (CP) is a widely used chemotherapeutic drug and immunosuppressant in the clinic, and the hypoandrogenism caused by CP is receiving more attention. Some studies found that ferroptosis is a new mechanism of cell death closely related to chemotherapeutic drugs and plays a key role in regulating reproductive injuries. The purpose of this study is to explore ferroptosis’ role in testicular Leydig cell dysfunction and molecular mechanisms relating to it. In this study, the level of ferroptosis in the mouse model of testicular Leydig cell dysfunction induced by CP was significantly increased and further affected testosterone synthesis. The ferroptosis inhibitors ferrostatin-1 (Fer-1) and iron chelator deferoxamine (DFO) can improve injury induced by CP. The results of immunohistochemistry showed that Fer-1 and DFO could improve the structural disorder of seminiferous tubules and the decrease of the number of Leydig cells in testicular tissue induced by CP. Immunofluorescence and western blot confirmed that Fer-1 and DFO could improve the expression of key enzymes in testosterone synthesis. The activation of SMAD family member 2 (Smad2)/cyclin-dependent kinase inhibitor 1A (Cdkn1a) pathway can improve the ferroptosis of Leydig cells induced by CP and protect the function of Leydig cells. By inhibiting the Smad2/Cdkn1a signal pathway, CP can regulate ferroptosis, resulting in testicular Leydig cell dysfunction. In this study, CP-induced hypoandrogenism is explained theoretically and a potential therapeutic strategy is provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, PR China.
- The Third School of Clinical Medicine, Southern Medical University, Guangzhou, PR China.
- Department of Urology, Shenzhen Baoan District Central Hospital, Shenzhen, PR China.
Förderung
- National Natural Science Foundation of China
- Third Affiliated Hospital of Southern Medical University President's Fund
- Third Affiliated Hospital of Southern Medical University President’s Fund
Zitieren
APA
Liao, S., Wei, C., Wei, G., Liang, H., Peng, F., Zhao, L., Li, Z., Liu, C., & Zhou, Q. (2024). Cyclophosphamide activates ferroptosis-induced dysfunction of Leydig cells via SMAD2 pathway. Biology of Reproduction. https://doi.org/10.1093/biolre/ioae020
Vancouver
Liao S, Wei C, Wei G, Liang H, Peng F, Zhao L, et al. Cyclophosphamide activates ferroptosis-induced dysfunction of Leydig cells via SMAD2 pathway. Biology of Reproduction. 2024. doi:10.1093/biolre/ioae020
BibTeX
@article{Liao2024,
author = {Liao, Senlin and Wei, Cun and Wei, Guanyang and Liang, Haoyu and Peng, Fan and Zhao, Lei and Li, Ziguang and Liu, Cundong and Zhou, Qizhao},
title = {Cyclophosphamide activates ferroptosis-induced dysfunction of Leydig cells via SMAD2 pathway},
journal = {Biology of Reproduction},
year = {2024},
doi = {10.1093/biolre/ioae020}
}
EUVIMED